Clinical Trial for Evaluating the Effectiveness and Safety of the Pulse Wave-based Atrial Fibrillation and Premature Beat Alert Software

Inclusion Criteria: 1. Patients over 18 years old, regardless of gender; 2. Participants who meet one of the following conditions according to the medical history in the past 3 months or the ECG during the screening period: 1. Patients with normal sinus rhythm; 2. Patients with persistent or permanent paroxysmal atrial fibrillation or in the onset of paroxysmal atrial fibrillation; 3. Patients with frequent premature beats (more than 5 per minute) or in the onset of premature beats; 3. Patients who volunteer to participate and have signed an informed consent form. Exclusion Criteria: 1. Patients using cardiac pacemakers or implantable cardioverter defibrillators (ICD); 2. Patients with non-respiratory sinus arrhythmia, sinus arrest or sick sinus syndrome according to the ECG results during the screening period; 3. Patients with interpolated premature beats, junctional premature beats, or escape rhythms according to the ECG results during the screening period; 4. Patients with atrial flutter, ventricular flutter, or ventricular fibrillation according to the ECG results during the screening period; 5. Patients with atrial fibrillation or premature beats who have a resting heart rate of slower than 50 beats/minute or faster than 110 beats/minute according to the ECG results during the screening period; 6. Patients who are critically ill, making it difficult to make an accurate assessment of the effectiveness and safety of the device; 7. Patients who suffer from tremor diseases or chorea, making it difficult to complete the examination quietly; 8. Patients with bullous diseases or large-area skin rashes that are not suitable for body surface electrode recording; 9. Patients whose skin is allergic to ethanol; 10. Patients with contagious skin diseases; 11. Patients with tattoos on their wrist skin that is to be measured; 12. Patients with poor compliance who are unable to cooperate to complete this investigation on their own; 13. Patients who have participated in other clinical investigations within the past 30 days that may affect this investigation; 14. Other conditions that the investigators consider inappropriate for participation in the investigation.